These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 30149394)

  • 21. Postoperative Infectious Complications are Associated with Adverse Oncologic Outcomes in Esophageal Cancer Patients Undergoing Preoperative Chemotherapy.
    Yamashita K; Makino T; Miyata H; Miyazaki Y; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
    Ann Surg Oncol; 2016 Jun; 23(6):2106-14. PubMed ID: 26753750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant Chemoradiotherapy for Patients with cT3/Nearly T4 Esophageal Cancer: Is Sarcopenia Correlated with Postoperative Complications and Prognosis?
    Saeki H; Nakashima Y; Kudou K; Sasaki S; Jogo T; Hirose K; Edahiro K; Korehisa S; Taniguchi D; Nakanishi R; Kubo N; Ando K; Kabashima A; Oki E; Maehara Y
    World J Surg; 2018 Sep; 42(9):2894-2901. PubMed ID: 29488065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protocol of a pilot randomized clinical trial to evaluate nutritional support and rehabilitation on prevention of skeletal muscle mass loss during neoadjuvant chemotherapy in patients with esophageal cancer.
    Miki Y; Nishi S; Tamura T; Imai T; Nambara M; Fukuoka T; Yoshii M; Toyokawa T; Lee S; Fujii H; Yoshida H; Ikebuchi M; Maeda K
    PLoS One; 2024; 19(4):e0302003. PubMed ID: 38635741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant chemoradiotherapy followed by esophagectomy does not increase morbidity in patients over 70.
    Blom RL; van Heijl M; Klinkenbijl JH; Bergman JJ; Wilmink JW; Richel DJ; Hulshof MC; Reitsma JB; Busch OR; van Berge Henegouwen MI
    Dis Esophagus; 2013 Jul; 26(5):510-6. PubMed ID: 22925313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer.
    Yip C; Goh V; Davies A; Gossage J; Mitchell-Hay R; Hynes O; Maisey N; Ross P; Gaya A; Landau DB; Cook GJ; Griffin N; Mason R
    Eur Radiol; 2014 May; 24(5):998-1005. PubMed ID: 24535076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Why are patients being readmitted after surgery for esophageal cancer?
    Shah SP; Xu T; Hooker CM; Hulbert A; Battafarano RJ; Brock MV; Mungo B; Molena D; Yang SC
    J Thorac Cardiovasc Surg; 2015 May; 149(5):1384-9; discussion 1389-91. PubMed ID: 25983251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sarcopenia as a predictor of pulmonary complications after esophagectomy for thoracic esophageal cancer.
    Nishigori T; Okabe H; Tanaka E; Tsunoda S; Hisamori S; Sakai Y
    J Surg Oncol; 2016 May; 113(6):678-84. PubMed ID: 26936808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: A nationwide study.
    van der Werf LR; Dikken JL; van der Willik EM; van Berge Henegouwen MI; Nieuwenhuijzen GAP; Wijnhoven BPL;
    Eur J Cancer; 2018 Mar; 91():76-85. PubMed ID: 29353163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
    Aoyama S; Motoori M; Yamasaki M; Shiraishi O; Miyata H; Hirao M; Takeno A; Sugimura K; Makino T; Tanaka K; Hamakawa T; Yamashita K; Kimura Y; Fujitani K; Yasuda T; Yano M; Doki Y
    Esophagus; 2023 Apr; 20(2):225-233. PubMed ID: 36494496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantity and Quality of Skeletal Muscle as an Important Predictor of Clinical Outcomes in Patients with Esophageal Cancer Undergoing Esophagectomy after Neoadjuvant Chemotherapy.
    Ishida T; Makino T; Yamasaki M; Yamashita K; Tanaka K; Saito T; Yamamoto K; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Eguchi H; Doki Y
    Ann Surg Oncol; 2021 Nov; 28(12):7185-7195. PubMed ID: 33876359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients.
    Anandavadivelan P; Brismar TB; Nilsson M; Johar AM; Martin L
    Clin Nutr; 2016 Jun; 35(3):724-30. PubMed ID: 26065721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of sarcopenia on outcome in patients with esophageal resection following neoadjuvant chemotherapy for esophageal cancer.
    Paireder M; Asari R; Kristo I; Rieder E; Tamandl D; Ba-Ssalamah A; Schoppmann SF
    Eur J Surg Oncol; 2017 Feb; 43(2):478-484. PubMed ID: 28024944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse Effects of Preoperative Sarcopenia on Postoperative Complications of Patients With Gastric Cancer.
    Tamura T; Sakurai K; Nambara M; Miki Y; Toyokawa T; Kubo N; Tanaka H; Muguruma K; Yashiro M; Ohira M
    Anticancer Res; 2019 Feb; 39(2):987-992. PubMed ID: 30711985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Muscle wasting and survival following pre-operative chemoradiotherapy for locally advanced rectal carcinoma.
    Levolger S; van Vledder MG; Alberda WJ; Verhoef C; de Bruin RWF; IJzermans JNM; Burger JW
    Clin Nutr; 2018 Oct; 37(5):1728-1735. PubMed ID: 28756039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of skeletal muscle loss with the long-term outcomes of esophageal cancer patients treated with neoadjuvant chemotherapy.
    Kamitani N; Migita K; Matsumoto S; Wakatsuki K; Kunishige T; Nakade H; Miyao S; Sho M
    Surg Today; 2019 Dec; 49(12):1022-1028. PubMed ID: 31309328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sarcopenia during neoadjuvant therapy for oesophageal cancer: characterising the impact on muscle strength and physical performance.
    Guinan EM; Doyle SL; Bennett AE; O'Neill L; Gannon J; Elliott JA; O'Sullivan J; Reynolds JV; Hussey J
    Support Care Cancer; 2018 May; 26(5):1569-1576. PubMed ID: 29197960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of sarcopenia in patients undergoing esophagectomy for superficial esophageal squamous cell carcinoma.
    Oguma J; Ozawa S; Kazuno A; Yamamoto M; Ninomiya Y; Yatabe K
    Dis Esophagus; 2019 Jul; 32(7):. PubMed ID: 30809629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sarcopenia, the depletion of muscle mass, an independent predictor of respiratory complications after oncological esophagectomy.
    Soma D; Kawamura YI; Yamashita S; Wake H; Nohara K; Yamada K; Kokudo N
    Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30239649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative chemoradiation therapy for esophageal cancer is a risk factor for the elevation of high mobility group box-1, leading to an increase in postoperative severe pulmonary complications.
    Takahata R; Ono S; Tsujimoto H; Hiraki S; Aosasa S; Yamamoto J; Hase K
    Dis Esophagus; 2016 Jan; 29(1):70-8. PubMed ID: 25139532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic impact of shift to low visceral fat mass after neoadjuvant chemotherapy in patients with esophageal cancer.
    Onishi S; Tajika M; Tanaka T; Yamada K; Inaba Y; Abe T; Muro K; Shimizu M; Niwa Y
    Cancer Rep (Hoboken); 2024 Aug; 7(8):e2084. PubMed ID: 39158194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.